Holen Sie sich die Stockscreener-App
10.42
0.57%
-0.06
Handel nachbörslich:
10.42
Schlusskurs vom Vortag:
$10.48
Offen:
$10.47
24-Stunden-Volumen:
236.56K
Relative Volume:
0.83
Marktkapitalisierung:
$388.01M
Einnahmen:
$65.42M
Nettoeinkommen (Verlust:
$-32.96M
KGV:
-8.2047
EPS:
-1.27
Netto-Cashflow:
$-19.87M
1W Leistung:
-1.42%
1M Leistung:
-20.09%
6M Leistung:
-10.02%
1J Leistung:
+44.12%
1-Tages-Spanne:
$10.20
$10.60
1-Wochen-Bereich:
$10.10
$11.53
52-Wochen-Spanne:
$5.45
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Firmenname
Neuropace Inc
Sektor
Branche
Telefon
(650) 237-2700
Adresse
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Vergleichen Sie NPCE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
10.42 | 388.01M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
134.11 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.63 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
391.81 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.28 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.02 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-03-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Eingeleitet | Lake Street | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-05-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
NeuroPace, Inc. (NPCE) Backed by Cantor Fitzgerald Following Physician Survey - MSN
Metric Analysis: NeuroPace Inc (NPCE)’s Key Ratios in the Limelight - DWinneX
NeuroPace stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com India
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc.NPCE - FinancialContent
Two Sigma Investments LP Invests $293,000 in NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
Cantor Fitzgerald Comments on NeuroPace FY2026 Earnings - MarketBeat
Bank of America Corp DE Raises Position in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect - ACCESS Newswire
Research Analysts Set Expectations for NeuroPace Q2 Earnings - MarketBeat
NeuroPace Holds Virtual Annual Stockholders Meeting - TipRanks
NeuroPace’s SWOT analysis: med tech stock poised for growth amid challenges By Investing.com - Investing.com South Africa
NeuroPace’s SWOT analysis: med tech stock poised for growth amid challenges - Investing.com
NeuroPace Inc (NPCE) Shares Down 3.25% on Jun 12 - GuruFocus
Potential Securities Fraud: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) - ACCESS Newswire
NeuroPace stock maintains buy rating at UBS following physician survey By Investing.com - Investing.com India
NeuroPace stock maintains buy rating at UBS following physician survey - Investing.com
Cantor Fitzgerald Estimates NeuroPace FY2026 Earnings - Defense World
Fraud Investigation: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) on Behalf of Shareholders - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Two Sigma Investments LP Makes New Investment in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
NPCE ALERT: Ongoing Investigation Into NeuroPace, Inc.Contact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) Over Possible Securities Fraud - ACCESS Newswire
Did NeuroPace, Inc. (NPCE) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
Q2 Earnings Forecast for NeuroPace Issued By Leerink Partnrs - Defense World
Two Sigma Advisers LP Purchases New Position in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
Ongoing Investigation into NeuroPace, Inc. (NPCE): Contact Levi & Korsinsky About Potential Fraud - ACCESS Newswire
NeuroPace secures USD 75M in debt financing - Medical Buyer
BNP Paribas Financial Markets Acquires New Holdings in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
NeuroPace Secures $75 Million Credit Facility with MidCap - TipRanks
NeuroPace Secures $75 Million Credit Facility From MidCap Financial - marketscreener.com
NeuroPace secures $75 million credit facility with MidCap Financial - Investing.com Australia
NeuroPace secures $75 million credit facility with MidCap Financial By Investing.com - Investing.com Canada
Neuropace IncEnters Into Credit Agreement With Midcap Funding Iv Trust - MarketScreener
NeuroPace Secures Up to $75 Million in Debt Financing - The Manila Times
NeuroPace, Inc. Secures $75 Million Credit Facility from MidCap Financial to Support Growth Initiatives - Nasdaq
$75M Financing Fuels NeuroPace's Epilepsy Treatment Expansion: 5 Key Growth Initiatives Revealed - Stock Titan
Lost Money on NeuroPace, Inc. (NPCE)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Lost Investment in NeuroPace, Inc. (NPCE)? Levi & Korsinsky Launches Securities Fraud Investigation - ACCESS Newswire
FY2028 EPS Estimates for NeuroPace Cut by Leerink Partnrs - MarketBeat
What is HC Wainwright's Forecast for NeuroPace Q2 Earnings? - MarketBeat
NPCE ACTIVE INVESTIGATION: Lost Money on NeuroPace, Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Stockholders to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeuroPace, ... - Bluefield Daily Telegraph
Finanzdaten der Neuropace Inc-Aktie (NPCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neuropace Inc-Aktie (NPCE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Morrell Martha | CHIEF MEDICAL OFFICER |
Feb 21 '25 |
Sale |
13.72 |
78,334 |
1,074,844 |
81,993 |
| KCK LTD. | 10% Owner |
Feb 20 '25 |
Sale |
9.40 |
5,270,845 |
49,545,943 |
0 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 30 '25 |
Sale |
15.00 |
200 |
3,000 |
86,762 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 29 '25 |
Sale |
15.00 |
100 |
1,500 |
86,962 |
0.54%
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):